Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: Expert recommendations
- PMID: 35434900
- PMCID: PMC9366572
- DOI: 10.1111/1753-0407.13266
Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: Expert recommendations
Abstract
The upsurge of type 2 diabetes mellitus is a major public health concern in the Middle East and North Africa (MENA) and Africa (AFR) region, with cardiorenal complications (CRCs) being the predominant cause of premature morbidity and mortality. High prevalence of cardiometabolic risk factors, lack of awareness among patients and physicians, deficient infrastructure, and economic constraints lead to a cascade of CRCs at a significantly earlier age in MENA and AFR. In this review, we present consensus recommendations by experts in MENA and AFR, highlighting region-specific challenges and potential solutions for management of CRCs. Health professionals who understand sociocultural barriers can significantly increase patient awareness and encourage health-seeking behavior through simple educational tools. Increasing physician knowledge on early identification of CRCs and personalized treatment based on risk stratification, alongside optimum glycemic control, can mitigate therapeutic inertia. Early diagnosis of high-risk people with regular and systematic monitoring of cardiorenal parameters, development of region-specific care pathways for timely referral to specialists, followed by guideline-recommended care with novel antidiabetics are imperative. Adherence to guideline-recommended care can catalyze utilization of sodium glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists with demonstrated cardiorenal benefits-thus paving the way for overcoming care gaps in a cost-effective manner. Leveraging digital technology like electronic medical records can help generate real-world data and provide insights on voids in adoption of newer antidiabetic medications. A patient-centric approach, collaborative care among physicians from different specialties, alongside involvement of policy makers are key for improving patient outcomes and quality of care in MENA and AFR.
2型糖尿病是中东及北非(MENA)和非洲(AFR)地区的一大公共卫生问题,心肾并发症(CRC)是过早发病和死亡的主要原因。心脏代谢危险因素的高发、患者和医生缺乏认识、基础设施不足以及经济限制导致MENA和AFR患者的CRC年龄显著提前。在这篇综述中,我们提出了MENA和AFR地区专家的共识和建议,强调了区域特有的挑战和潜在的区域控制中心管理解决方案。了解社会文化障碍的卫生专业人员可以通过简单的教育工具显著提高患者的意识并鼓励寻求健康的行为。增加医生在早期识别CRC和基于风险分层的个性化治疗方面的知识,同时更好地控制血糖,从而减轻治疗的惰性。必须对高危人群进行早期诊断,对心肾功能进行定期和系统的监测,制定特定区域的护理路径,及时转诊至专家,然后根据指南建议的治疗,使用新型抗糖尿病药物。遵循指南推荐的治疗可以使用钠葡萄糖共转运体2抑制剂和胰高血糖素样肽1受体激动剂,它们已被证明对心肾有好处,从而以经济高效的方式为治疗技术的鸿沟铺平道路。利用数字技术,如电子病历,可以辅助生成真实世界的数据,以填补对较新的抗糖尿病药物效果观察的空白。以患者为中心的方法、不同专科医生之间的协作护理以及政策制定者的参与是改善MENA和AFR地区患者结局和治疗质量的关键。.
Keywords: 2型糖尿病; Middle East and North Africa and Africa; cardiovascular risk management; diabetic cardiomyopathy; diabetic kidney disease; type 2 diabetes mellitus; 中东和非洲; 心血管风险管理; 糖尿病心肌病; 糖尿病肾病.
© 2022 The Authors. Journal of Diabetes published by Ruijin Hospital, Shanghai JiaoTong University School of Medicine and John Wiley & Sons Australia, Ltd.
Conflict of interest statement
M.H., A.E., A.M.R., A.M.A., F.S.S., F.H.H., H.I., S.A., Z.B., and Z.O.S. declare no competing interests. A.S. reports participation in advisory boards of AstraZeneca, Novo Nordisk, Novartis, Eli Lilly, and Sanofi; meeting and travel support from AstraZeneca, Novo Nordisk, Amgen, and Sanofi; honoraria for educational lectures from Novo Nordisk, Boehringer Ingelheim, and Sanofi, and being the principal investigator in studies by Novo Nordisk and Novartis. I.E. reports participation in advisory boards of Abbott, AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme, Novartis, Eli Lilly, Servier, Janssen, Novo Nordisk, Sanofi, EVA Pharma, Apex, and Amgen; participation as a speaker at AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme, Novartis, Eli Lilly, Servier, Janssen, Merck Serono, Novo Nordisk, Sanofi, Amgen, EVA Pharma, Apex, hikma, Marcyrl, and Abbott; and participation in clinical trial research at Merck Sharp & Dohme, Novartis, Servier, and Novo Nordisk. H.S. reports honoraria for educational lectures and licenses from Novartis, AstraZeneca, Boehringer Ingelheim, Novo Nordisk, MAD, and Merck Sharp and Dohme. S.A. reports speaker honoraria from AstraZeneca, Boehringer Ingelheim, Merck Sharp and Dohme, Merk Serono, Novo Nordisk, Novartis, and Sanofi Aventis. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or editorial, research, and writing support for the development of the recommendations for gaps in the management of T2DM in the MENA and AFR region apart from those disclosed.
Figures


Similar articles
-
Global survey investigating causes of treatment inertia in type 2 diabetes cardiorenal risk management.J Diabetes Complications. 2021 Mar;35(3):107813. doi: 10.1016/j.jdiacomp.2020.107813. Epub 2020 Nov 26. J Diabetes Complications. 2021. PMID: 33419634
-
Low Use of Guideline-recommended Cardiorenal Protective Antihyperglycemic Agents in Primary Care: A Cross-sectional Study of Adults With Type 2 Diabetes.Can J Diabetes. 2022 Jul;46(5):487-494. doi: 10.1016/j.jcjd.2022.02.002. Epub 2022 Feb 15. Can J Diabetes. 2022. PMID: 35739042
-
Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration.Curr Diab Rep. 2019 Dec 4;19(12):157. doi: 10.1007/s11892-019-1260-0. Curr Diab Rep. 2019. PMID: 31802265 Review.
-
Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect.Eur J Intern Med. 2022 Feb;96:26-33. doi: 10.1016/j.ejim.2021.11.008. Epub 2021 Nov 17. Eur J Intern Med. 2022. PMID: 34799233 Review.
-
Type 2 diabetes and pre-diabetes mellitus: a systematic review and meta-analysis of prevalence studies in women of childbearing age in the Middle East and North Africa, 2000-2018.Syst Rev. 2019 Nov 8;8(1):268. doi: 10.1186/s13643-019-1187-1. Syst Rev. 2019. PMID: 31703716 Free PMC article.
Cited by
-
Improving Therapeutic Adherence and Reducing Therapeutic Inertia in the Management of People with Cardiometabolic Diseases: A Call-to-Action from the Middle East.Adv Ther. 2025 Mar;42(3):1340-1359. doi: 10.1007/s12325-024-03103-5. Epub 2025 Jan 22. Adv Ther. 2025. PMID: 39841371 Free PMC article. Review.
-
The Inferential Binding Sites of GCGR for Small Molecules Using Protein Dynamic Conformations and Crystal Structures.Int J Mol Sci. 2024 Aug 1;25(15):8389. doi: 10.3390/ijms25158389. Int J Mol Sci. 2024. PMID: 39125959 Free PMC article.
-
Critical questions in diabetes management: What are the most compelling challenges and how can we handle them?Int J Cardiol Cardiovasc Risk Prev. 2022 Nov 18;15:200160. doi: 10.1016/j.ijcrp.2022.200160. eCollection 2022 Dec. Int J Cardiol Cardiovasc Risk Prev. 2022. PMID: 36573189 Free PMC article.
References
-
- IDF Diabetes Atlas 9 Edition 2019 . Global diabetes data report 2010. — 2045. Accessed March 12, 2021. https://diabetesatlas.org/data/
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials